Transgenic Plasmodium that expresses HIV-1 Gag elicits immunity and protects mice against vaccinia virus-gag and malarial parasites.

Malaria and human immunodeficiency virus type 1 (HIV-1) infection overlap in many regions of the world. Our goal was to determine the feasibility of developing transgenic Plasmodium berghei that expresses HIV-1 Gag, PbGAG, as a conceptual bivalent vaccine against both HIV-1 infection and malaria. Immunization of mice with PbGAG induced specific responses to the HIV-1 Gag. Importantly, mice vaccinated with PbGAG were significantly protected from challenge with vaccinia virus-gag (VV-gag) with an average 30-fold reduction in titer (P<0.05). In addition, mice immunized with PbGAG developed Plasmodium-specific immune responses and the immunized animals were protected from challenges with blood-stage P. berghei NK65 and Plasmodium yoelii 17XL. We demonstrated a novel vaccination strategy that uses a live transgenic protozoan parasite-based bivalent vaccine to immunize mice and confer significant levels of protection against VV-gag and malarial parasite challenges. These observations have important implications for the development of a new form of bivalent vaccine against both HIV-1 and malaria.